Search research articles
Contact Us
Filters
Showing results (641-650 of 715) with videos related to
Page
of 72
Sort By:
Blood
|
September 10, 2005
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
Florian Heidel, Fian K Solem, Frank Breitenbuecher, et al.
Leukemia
|
July 12, 2020
Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
Carl C Crodel, Kathleen Jentsch-Ullrich, Steffen Koschmieder, et al.
Leukemia
|
February 25, 2025
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN)
Kirsi Manz, Florian H Heidel, Steffen Koschmieder, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 3, 2016
Selenoprotein H is an essential regulator of redox homeostasis that cooperates with p53 in development and tumorigenesis
Andrew G Cox, Allison Tsomides, Andrew J Kim, et al.
Leukemia
|
November 17, 2019
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations
Rebecca J Austin, Jasmin Straube, Claudia Bruedigam, et al.
Leukemia
|
September 1, 2021
YBX1 mediates translation of oncogenic transcripts to control cell competition in AML
Florian Perner, Tina M Schnoeder, Yijun Xiong, et al.
Annals of Hematology
|
March 13, 2024
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study
F Palandri, G Auteri, E Abruzzese, et al.
Annals of Hematology
|
December 23, 2022
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
Steffen Koschmieder, Susanne Isfort, Dominik Wolf, et al.
Hemasphere
|
March 25, 2025
Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey
Claire N Harrison, David M Ross, Laura Maria Fogliatto, et al.
The Journal of Clinical Investigation
|
July 20, 2018
JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation
Bärbel Edelmann, Nibedita Gupta, Tina M Schnoeder, et al.
Page
of 72
Search research articles
Search
Showing results (641-650 of 715) with videos related to
Sort By:
Page
of 72
Blood
|
September 10, 2005
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
Florian Heidel, Fian K Solem, Frank Breitenbuecher, et al.
Leukemia
|
July 12, 2020
Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
Carl C Crodel, Kathleen Jentsch-Ullrich, Steffen Koschmieder, et al.
Leukemia
|
February 25, 2025
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN)
Kirsi Manz, Florian H Heidel, Steffen Koschmieder, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 3, 2016
Selenoprotein H is an essential regulator of redox homeostasis that cooperates with p53 in development and tumorigenesis
Andrew G Cox, Allison Tsomides, Andrew J Kim, et al.
Leukemia
|
November 17, 2019
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations
Rebecca J Austin, Jasmin Straube, Claudia Bruedigam, et al.
Leukemia
|
September 1, 2021
YBX1 mediates translation of oncogenic transcripts to control cell competition in AML
Florian Perner, Tina M Schnoeder, Yijun Xiong, et al.
Annals of Hematology
|
March 13, 2024
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study
F Palandri, G Auteri, E Abruzzese, et al.
Annals of Hematology
|
December 23, 2022
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group
Steffen Koschmieder, Susanne Isfort, Dominik Wolf, et al.
Hemasphere
|
March 25, 2025
Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey
Claire N Harrison, David M Ross, Laura Maria Fogliatto, et al.
The Journal of Clinical Investigation
|
July 20, 2018
JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation
Bärbel Edelmann, Nibedita Gupta, Tina M Schnoeder, et al.
Page
of 72